<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01137136</url>
  </required_header>
  <id_info>
    <org_study_id>2009-11-035</org_study_id>
    <nct_id>NCT01137136</nct_id>
  </id_info>
  <brief_title>Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea</brief_title>
  <acronym>CYP19</acronym>
  <official_title>Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aromatase(CYP19)inhibitor is one of the major antihormonal drug for breast cancer in
      postmenopausal women. The variation of CYP19 may affect the effect of aromatase inhibitor.
      However, the incidence of variation of CYP19 in Korea has not known. Therefore, the
      investigators want to know the incidence of variation of CYP19 and to assess the effect of
      these variations of CYP19 to aromatase inhibitor users.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Because of economic issue, we could just enrolled total 150 patients.
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The prevalence of CYP19 polymorphism</measure>
    <time_frame>12. 31. 2011</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effect of CYP19 polymorphism to the prognosis of AI user</measure>
    <time_frame>12. 31. 2016</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Polymorphism</condition>
  <condition>CYP19</condition>
  <condition>Aromatase Inhibitor</condition>
  <arm_group>
    <arm_group_label>SMAC (SMc AI user Cohort)</arm_group_label>
    <description>All patients who took the AI (Aromatase inhibitor)will be enrolled</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Postmenopausa women who underwent surgery for breast cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hormone receptor positiveBreast cancer patient

          -  postmenopausal women

          -  first user of aromatase inhibitor

        Exclusion Criteria:

          -  premenopausal

          -  The patient who take the other antihormonal therapy

          -  osteoporosis patients
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seok Jin Nam, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2010</study_first_submitted>
  <study_first_submitted_qc>June 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2010</study_first_posted>
  <last_update_submitted>April 18, 2014</last_update_submitted>
  <last_update_submitted_qc>April 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Seok Jin Nam</investigator_full_name>
    <investigator_title>Professor, M.D., Ph.D.</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

